Vical attracts BMS with Vaxfectin adjuvant, pDNA drug discovery tech
This article was originally published in Scrip
Vical has signed an agreement with the first licensee for Vaxfectin, granting Bristol-Myers Squibb non-exclusive worldwide rights to the San Diego, US-based company's DNA vaccine adjuvant and also DNA immunisation technology for use in the discovery and production of therapeutic antibodies.
You may also be interested in...
TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.